206 related articles for article (PubMed ID: 28694658)
1. Anti-steatotic and anti-fibrotic effects of the KCa3.1 channel inhibitor, Senicapoc, in non-alcoholic liver disease.
Paka L; Smith DE; Jung D; McCormack S; Zhou P; Duan B; Li JS; Shi J; Hao YJ; Jiang K; Yamin M; Goldberg ID; Narayan P
World J Gastroenterol; 2017 Jun; 23(23):4181-4190. PubMed ID: 28694658
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of the potassium channel K
Staal RGW; Khayrullina T; Zhang H; Davis S; Fallon SM; Cajina M; Nattini ME; Hu A; Zhou H; Poda SB; Zorn S; Chandrasena G; Dale E; Cambpell B; Biilmann Rønn LC; Munro G; Mӧller T
Eur J Pharmacol; 2017 Jan; 795():1-7. PubMed ID: 27876619
[TBL] [Abstract][Full Text] [Related]
3. Anti-inflammatory and anti-fibrotic effects of modafinil in nonalcoholic liver disease.
Choi S; Kim JA; Li H; Jo SE; Lee H; Kim TH; Kim M; Kim SJ; Suh SH
Biomed Pharmacother; 2021 Dec; 144():112372. PubMed ID: 34794237
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of the K
Organ L; Bacci B; Koumoundouros E; Kimpton WG; Samuel CS; Nowell CJ; Bradding P; Roach KM; Westall G; Jaffar J; Snibson KJ
Am J Respir Cell Mol Biol; 2017 Apr; 56(4):539-550. PubMed ID: 28060543
[TBL] [Abstract][Full Text] [Related]
5. Repurposing the K
Lee RD; Chen YJ; Nguyen HM; Singh L; Dietrich CJ; Pyles BR; Cui Y; Weinstein JR; Wulff H
Transl Stroke Res; 2024 Jun; 15(3):518-532. PubMed ID: 37088858
[TBL] [Abstract][Full Text] [Related]
6. K
Derseh HB; Dewage SNV; Perera KUE; Pagel CN; Koumoundouros E; Organ L; Snibson KJ
Sci Rep; 2019 Dec; 9(1):19893. PubMed ID: 31882807
[TBL] [Abstract][Full Text] [Related]
7. Repurposing the KCa3.1 inhibitor senicapoc for Alzheimer's disease.
Jin LW; Lucente JD; Nguyen HM; Singh V; Singh L; Chavez M; Bushong T; Wulff H; Maezawa I
Ann Clin Transl Neurol; 2019 Apr; 6(4):723-738. PubMed ID: 31019997
[TBL] [Abstract][Full Text] [Related]
8. The Clinically Tested Gardos Channel Inhibitor Senicapoc Exhibits Antimalarial Activity.
Tubman VN; Mejia P; Shmukler BE; Bei AK; Alper SL; Mitchell JR; Brugnara C; Duraisingh MT
Antimicrob Agents Chemother; 2016 Jan; 60(1):613-6. PubMed ID: 26459896
[TBL] [Abstract][Full Text] [Related]
9. (S)YS-51, a novel isoquinoline alkaloid, attenuates obesity-associated non-alcoholic fatty liver disease in mice by suppressing lipogenesis, inflammation and coagulation.
Park EJ; Kim YM; Kim HJ; Jang SY; Oh MH; Lee DH; Chang KC
Eur J Pharmacol; 2016 Oct; 788():200-209. PubMed ID: 27343380
[TBL] [Abstract][Full Text] [Related]
10. Human relaxin-2 attenuates hepatic steatosis and fibrosis in mice with non-alcoholic fatty liver disease.
Lee KC; Hsieh YC; Chan CC; Sun HJ; Huang YH; Hou MC; Lin HC
Lab Invest; 2019 Jul; 99(8):1203-1216. PubMed ID: 30918325
[TBL] [Abstract][Full Text] [Related]
11. K⁺-channel inhibition reduces portal perfusion pressure in fibrotic rats and fibrosis associated characteristics of hepatic stellate cells.
Freise C; Heldwein S; Erben U; Hoyer J; Köhler R; Jöhrens K; Patsenker E; Ruehl M; Seehofer D; Stickel F; Somasundaram R
Liver Int; 2015 Apr; 35(4):1244-52. PubMed ID: 25212242
[TBL] [Abstract][Full Text] [Related]
12. Co-staining of K
Brömmel K; Maskri S; Bulk E; Pethő Z; Rieke M; Budde T; Koch O; Schwab A; Wünsch B
ChemMedChem; 2020 Dec; 15(24):2462-2469. PubMed ID: 33043595
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of MD2-dependent inflammation attenuates the progression of non-alcoholic fatty liver disease.
Zhang Y; Wu B; Zhang H; Ge X; Ying S; Hu M; Li W; Huang Y; Wang L; Chen C; Shan X; Liang G
J Cell Mol Med; 2018 Feb; 22(2):936-947. PubMed ID: 29077272
[TBL] [Abstract][Full Text] [Related]
14. Downregulation of microRNA-451 in non-alcoholic steatohepatitis inhibits fatty acid-induced proinflammatory cytokine production through the AMPK/AKT pathway.
Hur W; Lee JH; Kim SW; Kim JH; Bae SH; Kim M; Hwang D; Kim YS; Park T; Um SJ; Song BJ; Yoon SK
Int J Biochem Cell Biol; 2015 Jul; 64():265-76. PubMed ID: 25957914
[TBL] [Abstract][Full Text] [Related]
15. The pan-caspase inhibitor Emricasan (IDN-6556) decreases liver injury and fibrosis in a murine model of non-alcoholic steatohepatitis.
Barreyro FJ; Holod S; Finocchietto PV; Camino AM; Aquino JB; Avagnina A; Carreras MC; Poderoso JJ; Gores GJ
Liver Int; 2015 Mar; 35(3):953-66. PubMed ID: 24750664
[TBL] [Abstract][Full Text] [Related]
16. EX-527 Prevents the Progression of High-Fat Diet-Induced Hepatic Steatosis and Fibrosis by Upregulating SIRT4 in Zucker Rats.
Kundu A; Dey P; Park JH; Kim IS; Kwack SJ; Kim HS
Cells; 2020 Apr; 9(5):. PubMed ID: 32365537
[TBL] [Abstract][Full Text] [Related]
17. Baicalin attenuates non-alcoholic steatohepatitis by suppressing key regulators of lipid metabolism, inflammation and fibrosis in mice.
Zhang J; Zhang H; Deng X; Zhang N; Liu B; Xin S; Li G; Xu K
Life Sci; 2018 Jan; 192():46-54. PubMed ID: 29158052
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of NAMPT aggravates high fat diet-induced hepatic steatosis in mice through regulating Sirt1/AMPKα/SREBP1 signaling pathway.
Wang LF; Wang XN; Huang CC; Hu L; Xiao YF; Guan XH; Qian YS; Deng KY; Xin HB
Lipids Health Dis; 2017 Apr; 16(1):82. PubMed ID: 28449683
[TBL] [Abstract][Full Text] [Related]
19. Hepatocyte vitamin D receptor regulates lipid metabolism and mediates experimental diet-induced steatosis.
Bozic M; Guzmán C; Benet M; Sánchez-Campos S; García-Monzón C; Gari E; Gatius S; Valdivielso JM; Jover R
J Hepatol; 2016 Oct; 65(4):748-757. PubMed ID: 27245430
[TBL] [Abstract][Full Text] [Related]
20. The calcium-activated potassium channel KCa3.1 is an important modulator of hepatic injury.
Sevelsted Møller L; Fialla AD; Schierwagen R; Biagini M; Liedtke C; Laleman W; Klein S; Reul W; Koch Hansen L; Rabjerg M; Singh V; Surra J; Osada J; Reinehr R; de Muckadell OB; Köhler R; Trebicka J
Sci Rep; 2016 Jun; 6():28770. PubMed ID: 27354175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
